518 related articles for article (PubMed ID: 30308585)
21. Safety and Effectiveness of 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy After Regional Hepatic Embolization in Patients With Somatostatin-Expressing Neuroendocrine Tumors.
Hamiditabar M; Ali M; Bolek L; Vahdati G; Tworowska I; Delpassand ES
Clin Nucl Med; 2017 Nov; 42(11):822-828. PubMed ID: 28832377
[TBL] [Abstract][Full Text] [Related]
22.
Parghane RV; Talole S; Basu S
Ann Nucl Med; 2021 Jan; 35(1):92-101. PubMed ID: 33135123
[TBL] [Abstract][Full Text] [Related]
23. Peptide receptor radionuclide therapy for patients with advanced pancreatic neuroendocrine tumors.
Ramage J; Naraev BG; Halfdanarson TR
Semin Oncol; 2018 Aug; 45(4):236-248. PubMed ID: 30539715
[No Abstract] [Full Text] [Related]
24. Quality of Life in Patients with Metastatic Gastroenteropancreatic Neuroendocrine Tumors Receiving Peptide Receptor Radionuclide Therapy: Information from a Monitoring Program in Clinical Routine.
Martini C; Buxbaum S; Rodrigues M; Nilica B; Scarpa L; Holzner B; Virgolini I; Gamper EM
J Nucl Med; 2018 Oct; 59(10):1566-1573. PubMed ID: 30042164
[TBL] [Abstract][Full Text] [Related]
25. Long-term results and tolerability of tandem peptide receptor radionuclide therapy with
Kunikowska J; Pawlak D; Bąk MI; Kos-Kudła B; Mikołajczak R; Królicki L
Ann Nucl Med; 2017 Jun; 31(5):347-356. PubMed ID: 28316066
[TBL] [Abstract][Full Text] [Related]
26. Radiolabelled somatostatin analogue treatment in gastroenteropancreatic neuroendocrine tumours: factors associated with response and suggestions for therapeutic sequence.
Campana D; Capurso G; Partelli S; Nori F; Panzuto F; Tamburrino D; Cacciari G; Delle Fave G; Falconi M; Tomassetti P
Eur J Nucl Med Mol Imaging; 2013 Aug; 40(8):1197-205. PubMed ID: 23619938
[TBL] [Abstract][Full Text] [Related]
27. Peptide receptor radionuclide therapy (PRRT) for GEP-NETs.
Bergsma H; van Vliet EI; Teunissen JJ; Kam BL; de Herder WW; Peeters RP; Krenning EP; Kwekkeboom DJ
Best Pract Res Clin Gastroenterol; 2012 Dec; 26(6):867-81. PubMed ID: 23582925
[TBL] [Abstract][Full Text] [Related]
28. 177Lu-DOTATATE therapy in patients with neuroendocrine tumours including high-grade (WHO G3) neuroendocrine tumours: response to treatment and long-term survival update.
Demirci E; Kabasakal L; Toklu T; Ocak M; Şahin OE; Alan-Selcuk N; Araman A
Nucl Med Commun; 2018 Aug; 39(8):789-796. PubMed ID: 29912750
[TBL] [Abstract][Full Text] [Related]
29. Guidance on
Abbott A; Sakellis CG; Andersen E; Kuzuhara Y; Gilbert L; Boyle K; Kulke MH; Chan JA; Jacene HA; Van den Abbeele AD
J Nucl Med Technol; 2018 Sep; 46(3):237-244. PubMed ID: 30076245
[No Abstract] [Full Text] [Related]
30. Peptide Receptor Radionuclide Therapy With 177Lu-Octreotate in Patients With Somatostatin Receptor Expressing Neuroendocrine Tumors: Six Years' Assessment.
Hamiditabar M; Ali M; Roys J; Wolin EM; OʼDorisio TM; Ranganathan D; Tworowska I; Strosberg JR; Delpassand ES
Clin Nucl Med; 2017 Jun; 42(6):436-443. PubMed ID: 28263217
[TBL] [Abstract][Full Text] [Related]
31. 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy: Dose Response in Small Intestinal Neuroendocrine Tumors.
Jahn U; Ilan E; Sandström M; Garske-Román U; Lubberink M; Sundin A
Neuroendocrinology; 2020; 110(7-8):662-670. PubMed ID: 31597134
[TBL] [Abstract][Full Text] [Related]
32. Personalized
Del Prete M; Buteau FA; Arsenault F; Saighi N; Bouchard LO; Beaulieu A; Beauregard JM
Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):728-742. PubMed ID: 30506283
[TBL] [Abstract][Full Text] [Related]
33. Ectopic Corticotropin-Producing Neuroendocrine Tumor of the Pancreas Treated With 177Lu DOTATATE Induction and Maintenance Peptide Receptor Radionuclide Therapy.
Makis W; McCann K; Riauka TA; McEwan AJ
Clin Nucl Med; 2016 Jan; 41(1):50-2. PubMed ID: 26359569
[TBL] [Abstract][Full Text] [Related]
34. Overview and Current Status of Peptide Receptor Radionuclide Therapy.
Bushnell DL; Bodeker KL
Surg Oncol Clin N Am; 2020 Apr; 29(2):317-326. PubMed ID: 32151363
[TBL] [Abstract][Full Text] [Related]
35. Super-selective hepatic arterial infusions as established technique ('ARETAIEION' Protocol) of [177Lu]DOTA-TATE in inoperable neuroendocrine liver metastases of gastro-entero-pancreatic (GEP) tumors.
Limouris GS; Karfis I; Chatzioannou A; Paphiti MI; Lyra M; Gennatas K; Nikou G; Voros D; Pragulidis GP; Polydorou AA; Gouliamos A
Q J Nucl Med Mol Imaging; 2012 Dec; 56(6):551-8. PubMed ID: 23358409
[TBL] [Abstract][Full Text] [Related]
36. Pitfalls in the response evaluation after peptide receptor radionuclide therapy with [
Brabander T; van der Zwan WA; Teunissen JJM; Kam BLR; de Herder WW; Feelders RA; Krenning EP; Kwekkeboom DJ
Endocr Relat Cancer; 2017 May; 24(5):243-251. PubMed ID: 28320783
[TBL] [Abstract][Full Text] [Related]
37. Peptide Receptor Radionuclide Therapy as First-Line Systemic Treatment in Advanced Inoperable/Metastatic Neuroendocrine Tumors.
Satapathy S; Mittal BR; Sood A; Sood A; Kapoor R; Gupta R
Clin Nucl Med; 2020 Sep; 45(9):e393-e399. PubMed ID: 32604121
[TBL] [Abstract][Full Text] [Related]
38. Safety and efficacy of everolimus in gastrointestinal and pancreatic neuroendocrine tumors after (177)Lu-octreotate.
Kamp K; Gumz B; Feelders RA; Kwekkeboom DJ; Kaltsas G; Costa FP; de Herder WW
Endocr Relat Cancer; 2013 Dec; 20(6):825-31. PubMed ID: 24036133
[TBL] [Abstract][Full Text] [Related]
39. [(111)In-DTPA]octreotide tumor uptake in GEPNET liver metastases after intra-arterial administration: an overview of preclinical and clinical observations and implications for tumor radiation dose after peptide radionuclide therapy.
Pool SE; Kam BL; Koning GA; Konijnenberg M; Ten Hagen TL; Breeman WA; Krenning EP; de Jong M; van Eijck CH
Cancer Biother Radiopharm; 2014 May; 29(4):179-87. PubMed ID: 24820805
[TBL] [Abstract][Full Text] [Related]
40. Surgical Feasibility, Determinants, and Overall Efficacy of Neoadjuvant
Parghane RV; Bhandare M; Chaudhari V; Ostwal V; Ramaswamy A; Talole S; Shrikhande SV; Basu S
J Nucl Med; 2021 Nov; 62(11):1558-1563. PubMed ID: 33637590
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
